{"id":"fluoxymesterone","rwe":[],"tags":[{"label":"Androgen","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Androgen receptor","category":"target"},{"label":"AR","category":"gene"},{"label":"G03BA01","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Bilateral Anorchia","category":"indication"},{"label":"Congenital myotonia, autosomal dominant form","category":"indication"},{"label":"Deficiency of testosterone biosynthesis","category":"indication"},{"label":"Delayed puberty","category":"indication"},{"label":"Hormone receptor positive malignant neoplasm of breast","category":"indication"},{"label":"Klinefelter's syndrome, XXY","category":"indication"},{"label":"Approved 1950s","category":"decade"},{"label":"Anabolic Agents","category":"pharmacology"},{"label":"Hormones","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":77.768,"date":"","count":9,"signal":"Secondary hypogonadism","source":"DrugCentral FAERS","actionTaken":"Reported 9 times (LLR=78)"},{"llr":59.57,"date":"","count":6,"signal":"Glucose tolerance decreased","source":"DrugCentral FAERS","actionTaken":"Reported 6 times (LLR=60)"}],"drugInteractions":[{"url":"/drug/warfarin","drug":"warfarin","action":"Monitor closely","effect":"May interact with Warfarin","source":"DrugCentral","drugSlug":"warfarin"}],"commonSideEffects":[{"effect":"Virilization (females)","drugRate":"","severity":"common","organSystem":""},{"effect":"Amenorrhea and menstrual irregularities (females)","drugRate":"","severity":"common","organSystem":""},{"effect":"Inhibition of gonadotropin secretion","drugRate":"","severity":"common","organSystem":""},{"effect":"Gynecomastia (males)","drugRate":"","severity":"common","organSystem":""},{"effect":"Penile erections - excessive frequency and duration (males)","drugRate":"","severity":"common","organSystem":""},{"effect":"Hirsutism","drugRate":"","severity":"common","organSystem":""},{"effect":"Male pattern baldness","drugRate":"","severity":"common","organSystem":""},{"effect":"Seborrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Acne","drugRate":"","severity":"common","organSystem":""},{"effect":"Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Increased or decreased libido","drugRate":"","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Anxiety","drugRate":"","severity":"common","organSystem":""},{"effect":"Depression","drugRate":"","severity":"common","organSystem":""},{"effect":"Generalized paresthesia","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Asthma","Benign prostatic hyperplasia","Body fluid retention","Breast Carcinoma in Males","Breast lump","Breastfeeding (mother)","Carcinoma of female breast","Cardiovascular event risk","Cerebrovascular accident","Chloasma","Chorea","Deep venous thrombosis","Dementia","Diabetes mellitus","Disease of liver","Disorder of coronary artery","Disorder of gallbladder","Edema","Endometrial carcinoma","Endometriosis","Epilepsy","Estrogen receptor positive tumor","Family history of malignant neoplasm of breast","Functional visual loss","Heart failure"],"specialPopulations":{"Pregnancy":"Category X. (see CONTRAINDICATIONS).","Paediatric use":"Androgen therapy should be used very cautiously in children and only by specialists who are aware of the adverse effects on bone maturation. Skeletal maturation must be monitored every six months by an X-ray of the hand and wrist (see INDICATIONS AND USAGE, and WARNINGS)."},"seriousAdverseEvents":[{"effect":"Hepatocellular neoplasms","drugRate":"","severity":"serious"},{"effect":"Peliosis hepatis","drugRate":"","severity":"serious"},{"effect":"Cholestatic jaundice","drugRate":"","severity":"serious"},{"effect":"Alterations in liver function tests","drugRate":"","severity":"serious"},{"effect":"Suppression of clotting factors II, V, VII, and X","drugRate":"","severity":"serious"},{"effect":"Bleeding in patients on concomitant anticoagulant therapy","drugRate":"","severity":"serious"},{"effect":"Polycythemia","drugRate":"","severity":"serious"},{"effect":"Oligospermia (males)","drugRate":"","severity":"serious"},{"effect":"Anaphylactoid reactions","drugRate":"","severity":"serious"},{"effect":"Hypersensitivity skin manifestations","drugRate":"","severity":"serious"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=FLUOXYMESTERONE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:14:49.686095+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:14:55.367181+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FLUOXYMESTERONE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:14:55.672101+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Androgen Receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:14:56.718265+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1445/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:14:56.380821+00:00"}},"allNames":"fluotestin","offLabel":[],"synonyms":["fluoxymesterone","androfluorene","androfluorone","fluotestin","fluoximesterone"],"timeline":[{"date":"1956-10-15","type":"positive","source":"DrugCentral","milestone":"FDA approval"}],"approvals":[{"date":"1956-10-15","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Fluotestin","ecosystem":[{"indication":"Bilateral Anorchia","otherDrugs":[{"name":"methyltestosterone","slug":"methyltestosterone","company":"Valeant Pharm Intl"},{"name":"testosterone","slug":"testosterone","company":"Actient Pharms"}],"globalPrevalence":null},{"indication":"Congenital myotonia, autosomal dominant form","otherDrugs":[],"globalPrevalence":80000},{"indication":"Deficiency of testosterone biosynthesis","otherDrugs":[{"name":"methyltestosterone","slug":"methyltestosterone","company":"Valeant Pharm Intl"},{"name":"testosterone","slug":"testosterone","company":"Actient Pharms"},{"name":"testosterone cypionate","slug":"testosterone-cypionate","company":"Watson Labs"},{"name":"testosterone enantate","slug":"testosterone-enantate","company":"Endo Pharms"}],"globalPrevalence":null},{"indication":"Delayed puberty","otherDrugs":[{"name":"methyltestosterone","slug":"methyltestosterone","company":"Valeant Pharm Intl"},{"name":"testosterone","slug":"testosterone","company":"Actient Pharms"},{"name":"testosterone cypionate","slug":"testosterone-cypionate","company":"Watson Labs"},{"name":"testosterone enantate","slug":"testosterone-enantate","company":"Endo Pharms"}],"globalPrevalence":null},{"indication":"Hormone receptor positive malignant neoplasm of breast","otherDrugs":[{"name":"abemaciclib","slug":"abemaciclib","company":"Eli Lilly And Co"},{"name":"anastrozole","slug":"anastrozole","company":"Astrazeneca"},{"name":"everolimus","slug":"everolimus","company":"Novartis"},{"name":"exemestane","slug":"exemestane","company":"Pharmacia And Upjohn"}],"globalPrevalence":null},{"indication":"Klinefelter's syndrome, XXY","otherDrugs":[{"name":"testosterone","slug":"testosterone","company":"Actient Pharms"},{"name":"testosterone cypionate","slug":"testosterone-cypionate","company":"Watson Labs"},{"name":"testosterone enantate","slug":"testosterone-enantate","company":"Endo Pharms"},{"name":"testosterone propionate","slug":"testosterone-propionate","company":"Watson Labs"}],"globalPrevalence":null},{"indication":"LHRH Deficiency","otherDrugs":[{"name":"methyltestosterone","slug":"methyltestosterone","company":"Valeant Pharm Intl"},{"name":"testosterone","slug":"testosterone","company":"Actient Pharms"},{"name":"testosterone cypionate","slug":"testosterone-cypionate","company":"Watson Labs"},{"name":"testosterone enantate","slug":"testosterone-enantate","company":"Endo Pharms"}],"globalPrevalence":null},{"indication":"Male hypogonadism","otherDrugs":[{"name":"methyltestosterone","slug":"methyltestosterone","company":"Valeant Pharm Intl"},{"name":"testosterone","slug":"testosterone","company":"Actient Pharms"},{"name":"testosterone cypionate","slug":"testosterone-cypionate","company":"Watson Labs"},{"name":"testosterone enantate","slug":"testosterone-enantate","company":"Endo Pharms"}],"globalPrevalence":null}],"mechanism":{"target":"Androgen receptor","novelty":"First-in-class","targets":[{"gene":"AR","source":"DrugCentral","target":"Androgen receptor","protein":"Androgen receptor"}],"moaClass":"Androgen Receptor Agonists","modality":"Small Molecule","drugClass":"Androgen","explanation":"","oneSentence":"","technicalDetail":"Fluotestin is a non-aromatizable, synthetic androgen that selectively binds to the androgen receptor (AR), activating the transcription of androgen-dependent genes and promoting the development and maintenance of male characteristics."},"commercial":{"launchDate":"1956","_launchSource":"DrugCentral (FDA 1956-10-15, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1210","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=FLUOXYMESTERONE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FLUOXYMESTERONE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T11:33:18.434687","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:14:58.025266+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"methyltestosterone","drugSlug":"methyltestosterone","fdaApproval":"1973-12-03","genericCount":20,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"testosterone","drugSlug":"testosterone","fdaApproval":"1972-07-13","patentExpiry":"Sep 27, 2027","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"fluoxymesterone","indications":{"approved":[{"name":"Bilateral Anorchia","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Males with bilateral anorchia"},{"name":"Congenital myotonia, autosomal dominant form","source":"DrugCentral","snomedId":57938005,"regulator":"FDA","eligibility":"Not specified","prevalenceClass":"1-9 / 100 000","globalPrevalence":80000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (1822774[PMID]_20301529[PMID])"},{"name":"Deficiency of testosterone biosynthesis","source":"DrugCentral","snomedId":38825009,"regulator":"FDA","eligibility":"Males with deficiency of testosterone biosynthesis"},{"name":"Delayed puberty","source":"DrugCentral","snomedId":400003000,"regulator":"FDA","eligibility":"Carefully selected males with clearly delayed puberty, familial pattern, not secondary to pathological disorder"},{"name":"Hormone receptor positive malignant neoplasm of breast","source":"DrugCentral","snomedId":417181009,"regulator":"FDA","eligibility":"Females with hormone receptor positive malignant neoplasm of breast, one to five years postmenopausal"},{"name":"Klinefelter's syndrome, XXY","source":"DrugCentral","snomedId":405769009,"regulator":"FDA","eligibility":"Not specified"},{"name":"LHRH Deficiency","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Males with idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation"},{"name":"Male hypogonadism","source":"DrugCentral","snomedId":48723006,"regulator":"FDA","eligibility":"Males with primary hypogonadism (congenital or acquired), testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectomy"},{"name":"Noonan's syndrome","source":"DrugCentral","snomedId":205824006,"regulator":"FDA","eligibility":"Not specified"},{"name":"Primary Hypogonadism due to Bilateral Torsion","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Males with primary hypogonadism due to bilateral torsion"},{"name":"Primary Hypogonadism due to Orchitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Undescended testicle","source":"DrugCentral","snomedId":204878001,"regulator":"FDA"}],"offLabel":[{"name":"Anemia","source":"DrugCentral","drugName":"FLUOXYMESTERONE","evidenceCount":64,"evidenceLevel":"strong"}],"pipeline":[]},"drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"methyltestosterone","brandName":"methyltestosterone","genericName":"methyltestosterone","approvalYear":"1973","relationship":"same-class"},{"drugId":"testosterone","brandName":"testosterone","genericName":"testosterone","approvalYear":"1972","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07095894","phase":"PHASE3","title":"A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia Control","status":"NOT_YET_RECRUITING","sponsor":"Jaeb Center for Health Research","startDate":"2026-03-01","conditions":["Myopia"],"enrollment":348,"completionDate":"2029-06-01"},{"nctId":"NCT06520124","phase":"NA","title":"Stellest Lens Wear in Adult Progressing Myopes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Ulster","startDate":"2024-10-17","conditions":["Myopia, Progressive"],"enrollment":42,"completionDate":"2027-12-30"},{"nctId":"NCT07326852","phase":"NA","title":"Hybrid Assistive Limb Application in Multiple Sclerosis Patients","status":"ENROLLING_BY_INVITATION","sponsor":"Ege University","startDate":"2025-10-08","conditions":["Multiple Sclerosis"],"enrollment":8,"completionDate":"2026-02-09"},{"nctId":"NCT05174780","phase":"NA","title":"Myopia Control With a Innovative Spectacle Lens","status":"COMPLETED","sponsor":"Essilor International","startDate":"2021-12-29","conditions":["Myopia"],"enrollment":159,"completionDate":"2025-10-20"},{"nctId":"NCT05697562","phase":"NA","title":"Evaluation of Superior Rectal Arterial Embolization in Hemorrhoidal Disease","status":"RECRUITING","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2023-06-01","conditions":["Hemorrhoids"],"enrollment":80,"completionDate":"2030-12-31"},{"nctId":"NCT06525571","phase":"PHASE3","title":"Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-12-20","conditions":["Bladder Cancer"],"enrollment":200,"completionDate":"2028-01-04"},{"nctId":"NCT07120165","phase":"","title":"Effectiveness of Myopia Control Interventions : A Comparison of Myopia Control in European Children, Adolescents and Young Adults With Defocus Incorporated Multiple Segments (DIMS) and Highly Aspherical Lenslets (HAL) Spectacles, Atropine, Lenses and Combined Treatments","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2024-10-20","conditions":["Myopia"],"enrollment":114,"completionDate":"2025-05-07"},{"nctId":"NCT06863675","phase":"PHASE3","title":"Highly Aspherical Lenslet (HAL) and Binocular Vision (BV) Disorders [HALT X(T) Study]","status":"NOT_YET_RECRUITING","sponsor":"Singapore National Eye Centre","startDate":"2025-06-01","conditions":["Myopia","Strabismus"],"enrollment":40,"completionDate":"2030-06-30"},{"nctId":"NCT06214611","phase":"NA","title":"Prospective Validation of Adaptive Radiotherapy (ART) in Patients With Head and Neck Tumors","status":"RECRUITING","sponsor":"University Hospital, Essen","startDate":"2023-11-15","conditions":["Head and Neck Cancer","Adaptive Radiotherapy","Radiation","Optimized Treatment","Protection of Organs at Risk","Dysphagia Reduction"],"enrollment":50,"completionDate":"2027-12-15"},{"nctId":"NCT06516380","phase":"NA","title":"Cyberdyne HAL, TecnoBody D-Wall, and Walker View 3.0 SCX Combined Treatment","status":"COMPLETED","sponsor":"Ankara Yildirim Beyazıt University","startDate":"2024-05-30","conditions":["Mosaicplasty","Cyberdyne","Single Joint","TecnoBody"],"enrollment":1,"completionDate":"2024-06-30"},{"nctId":"NCT04896268","phase":"NA","title":"Efficacy and Safety of RAdiofrequency Versus HAL- RAR DOppler in Hemorrhoidal Pathology","status":"RECRUITING","sponsor":"Elsan","startDate":"2023-01-03","conditions":["Hemorrhoids"],"enrollment":100,"completionDate":"2025-08"},{"nctId":"NCT04731064","phase":"","title":"Recurrence Rate of Hemorrhoidal Disease at 10 Years and More After HAL Doppler or HAL-RAR Intervention","status":"RECRUITING","sponsor":"University Hospital, Grenoble","startDate":"2023-01-06","conditions":["Hemorrhoidal Disease"],"enrollment":500,"completionDate":"2024-06-30"},{"nctId":"NCT03504826","phase":"NA","title":"Walking Rehabilitation After Spinal Cord Injury: Locomotor Training Using Adaptive Robotics","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brooks Rehabilitation","startDate":"2018-11-29","conditions":["Spinal Cord Injuries"],"enrollment":21,"completionDate":"2024-12"},{"nctId":"NCT05192655","phase":"","title":"Artificial Intelligence in Functional Imaging for Individualized Treatment of Head and Neck Squamous Cell Carcinoma Patients","status":"RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2021-12-01","conditions":["HNSCC"],"enrollment":250,"completionDate":"2026-12-01"},{"nctId":"NCT04454697","phase":"NA","title":"Tissue Retractors for Radiation Therapy of Head and Neck Tumors","status":"COMPLETED","sponsor":"University Hospital Heidelberg","startDate":"2020-07-23","conditions":["Head and Neck Cancer"],"enrollment":34,"completionDate":"2023-10-01"},{"nctId":"NCT01647763","phase":"NA","title":"Hemorrhoidal Artery Ligation and Rectoanal Repair Versus Stapled Hemorrhoidopexy","status":"UNKNOWN","sponsor":"Cantonal Hospital of St. Gallen","startDate":"2011-07","conditions":["Hemorrhoids"],"enrollment":84,"completionDate":"2024-12"},{"nctId":"NCT02216305","phase":"NA","title":"HAL-RAR Versus Hemorrhoidectomy in the Treatment of Grade III-IV Hemorrhoids. Prospective, Randomized Trial","status":"COMPLETED","sponsor":"Hospital Plató","startDate":"2014-09","conditions":["Hemorrhoids","Pain, Postoperative"],"enrollment":40,"completionDate":"2016-11"},{"nctId":"NCT02545205","phase":"NA","title":"New Technology for Individualised, Intensive Training of Gait After Stroke Study I","status":"TERMINATED","sponsor":"Danderyd Hospital","startDate":"2018-01-01","conditions":["Stroke","Ambulation Difficulty","Hemiparesis"],"enrollment":2,"completionDate":"2018-09-01"},{"nctId":"NCT04571463","phase":"","title":"Ethyl Glucuronide in Urine Samples of Pregnant Women Within the HUS ja PHHYKY Area","status":"COMPLETED","sponsor":"Hanna Kahila","startDate":"2020-10-01","conditions":["Fetal Alcohol Spectrum Disorders"],"enrollment":505,"completionDate":"2021-07-30"},{"nctId":"NCT04203810","phase":"NA","title":"Effectiveness and Tolerability of Ectoin® Mouth and Throat Spray Althaea Honey (ERS09)","status":"COMPLETED","sponsor":"Bitop AG","startDate":"2020-01-14","conditions":["Sore Throat","Acute Pharyngitis","Cough"],"enrollment":194,"completionDate":"2020-12-04"},{"nctId":"NCT05252325","phase":"NA","title":"Clinical Study on Hyaluronic Acid With Lidocaine for the Treatment of Moderate to Severe Nasolabial Folds","status":"UNKNOWN","sponsor":"Centro Medico Polispecialistico","startDate":"2022-02","conditions":["Nasolabial Folds"],"enrollment":50,"completionDate":"2023-03"},{"nctId":"NCT05160714","phase":"PHASE1","title":"Individualized Response-adaptive Radiation Dose Prescription in HNC Based on MRI","status":"UNKNOWN","sponsor":"University Hospital Tuebingen","startDate":"2022-01-01","conditions":["Head and Neck Cancer"],"enrollment":24,"completionDate":"2025-03-30"},{"nctId":"NCT05104138","phase":"","title":"Eplerenone Versus PDT: Comparative Study by OCTA","status":"COMPLETED","sponsor":"Federico II University","startDate":"2015-10-01","conditions":["Central Serous Chorioretinopathy"],"enrollment":30,"completionDate":"2017-11-30"},{"nctId":"NCT04863963","phase":"","title":"Milligan-Morgan Versus Dearterialization With Mucopexy","status":"COMPLETED","sponsor":"Università degli Studi dell'Aquila","startDate":"2021-07-01","conditions":["Hemorrhoids","Hemorrhoid Prolapse"],"enrollment":1000,"completionDate":"2021-09-25"},{"nctId":"NCT01282515","phase":"PHASE2,PHASE3","title":"Treatment of Female Genital Erosive Lichen Planus(GELP) With Hexaminolevulinate PDT","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2011-08","conditions":["Genital Lichen Planus"],"enrollment":40,"completionDate":"2014-10"},{"nctId":"NCT04778124","phase":"NA","title":"HAL-RAR Technique for Treating Hemorrhoids","status":"COMPLETED","sponsor":"Amalia Fleming General Hospital","startDate":"2010-01","conditions":["Hemorrhoidal Disease"],"enrollment":105,"completionDate":"2019-11"},{"nctId":"NCT04675177","phase":"PHASE2,PHASE3","title":"Polidocanol Foam VS Artery Ligation in Hemorrhoidal Disease","status":"COMPLETED","sponsor":"Universidade do Porto","startDate":"2019-09-01","conditions":["Hemorrhoids"],"enrollment":45,"completionDate":"2020-03-25"},{"nctId":"NCT02545088","phase":"NA","title":"New Technology for Individualised, Intensive Training of Gait After Stroke- Study II","status":"COMPLETED","sponsor":"Danderyd Hospital","startDate":"2015-10","conditions":["Stroke","Ambulation Difficulty","Hemiparesis"],"enrollment":48,"completionDate":"2019-10"},{"nctId":"NCT01774578","phase":"PHASE2,PHASE3","title":"Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"NewLink Genetics Corporation","startDate":"2013-02","conditions":["Non-small Cell Lung Cancer","Progression of Non-small Cell Lung Cancer","Non-small Cell Lung Cancer Recurrent"],"enrollment":135,"completionDate":"2016-06-18"},{"nctId":"NCT03547388","phase":"PHASE1","title":"Moderate Whole Body Hyperthermia for Patients Undergoing Re-irradiation for Head and Neck Cancer -Influence on the Tumor Microenvironment","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2018-07-01","conditions":["Head and Neck Neoplasms","Recurrence Tumor"],"enrollment":10,"completionDate":"2020-05-04"},{"nctId":"NCT02991885","phase":"PHASE1","title":"HAL-MPE1 Safety and Tolerability Study","status":"COMPLETED","sponsor":"HAL Allergy","startDate":"2016-12","conditions":["Peanut Allergy"],"enrollment":42,"completionDate":"2019-09"},{"nctId":"NCT01023620","phase":"NA","title":"HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2009-10","conditions":["HIV Infections"],"enrollment":4,"completionDate":"2010-05-31"},{"nctId":"NCT02012036","phase":"","title":"Study To Optimize Photodynamic Transurethral Resection of the Bladder (TUR-B) In Clinical Practice","status":"COMPLETED","sponsor":"Ipsen","startDate":"2013-07","conditions":["Photodynamic Transurethral Resection of the Bladder (TUR-B)"],"enrollment":400,"completionDate":"2014-07"},{"nctId":"NCT03758456","phase":"PHASE1","title":"HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-human","status":"COMPLETED","sponsor":"HAL Allergy","startDate":"2018-11-21","conditions":["Rhinitis, Allergic","Rhinoconjunctivitis, Allergic"],"enrollment":45,"completionDate":"2019-05-17"},{"nctId":"NCT02343575","phase":"PHASE4","title":"Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU","status":"TERMINATED","sponsor":"Stanford University","startDate":"2015-01","conditions":["Hyperactive Delirium","Mixed Delirium"],"enrollment":3,"completionDate":"2018-01"},{"nctId":"NCT02367547","phase":"PHASE1,PHASE2","title":"Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitizers: HAL and BF-200 ALA Versus MAL","status":"UNKNOWN","sponsor":"Joint Authority for Päijät-Häme Social and Health Care","startDate":"2015-03","conditions":["Neoplasms, Basal Cell","Carcinoma, Basal Cell","Photochemotherapy","Photosensitizing Agents"],"enrollment":117,"completionDate":"2025-12"},{"nctId":"NCT00651677","phase":"NA","title":"Hand Assisted Versus \"Pure\" Laparoscopic Assisted Proctectomy for Rectal Cancer","status":"WITHDRAWN","sponsor":"Weill Medical College of Cornell University","startDate":"2011-04","conditions":["Rectal Cancer"],"enrollment":0,"completionDate":"2012-12"},{"nctId":"NCT02625272","phase":"PHASE2","title":"A Novel Technique of HALS With CME and CVL for RCC","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2015-06","conditions":["Colon Neoplasms"],"enrollment":60,"completionDate":"2020-04"},{"nctId":"NCT03220594","phase":"","title":"Serum AMH Levels in Patients Who Underwent Hypogastric Artery Ligation","status":"COMPLETED","sponsor":"Kanuni Sultan Suleyman Training and Research Hospital","startDate":"2017-03-20","conditions":["AMH"],"enrollment":90,"completionDate":"2017-09-29"},{"nctId":"NCT02410915","phase":"NA","title":"A Comparison Between the Exoskeleton Hybrid Assistive Limb and Conventional Gait Training Early After Stroke","status":"COMPLETED","sponsor":"Danderyd Hospital","startDate":"2014-02","conditions":["Stroke","Gait, Hemiplegic","Ambulation Difficulty","Hemiparesis"],"enrollment":32,"completionDate":"2017-05"},{"nctId":"NCT02149342","phase":"PHASE1,PHASE2","title":"Daylight-mediated Photodynamic Therapy of Actinic Keratoses:Comparing 0.2%HAL With 16%MAL","status":"COMPLETED","sponsor":"Joint Authority for Päijät-Häme Social and Health Care","startDate":"2014-05","conditions":["Actinic Keratoses"],"enrollment":14,"completionDate":"2015-09"},{"nctId":"NCT02512211","phase":"","title":"Validation of Questionnaires HAL and HEP","status":"UNKNOWN","sponsor":"Universidad Católica San Antonio de Murcia","startDate":"2015-10","conditions":["Haemophilia"],"enrollment":60,"completionDate":"2016-10"},{"nctId":"NCT01256424","phase":"PHASE2","title":"Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia","status":"COMPLETED","sponsor":"Photocure","startDate":"2011-04","conditions":["Cervical Intraepithelial Neoplasia"],"enrollment":262,"completionDate":"2012-12"},{"nctId":"NCT02163018","phase":"PHASE1","title":"HAL-MPE1 First-in-human","status":"COMPLETED","sponsor":"HAL Allergy","startDate":"2014-06","conditions":["Peanut Allergy"],"enrollment":17,"completionDate":"2015-06"},{"nctId":"NCT01858454","phase":"PHASE3","title":"Hand-assisted Laparoscopic Surgery (HALS) for Myomectomy","status":"TERMINATED","sponsor":"CHA University","startDate":"2013-03","conditions":["Uterine Myomas"],"enrollment":21,"completionDate":"2015-04"},{"nctId":"NCT02372981","phase":"NA","title":"Doppler-guided Haemorrhoidal Artery Ligation With Suture Mucopexy vs. Suture Mucopexy Alone","status":"COMPLETED","sponsor":"Medical University Innsbruck","startDate":"2010-10","conditions":["Third Degree Hemorrhoids"],"enrollment":40,"completionDate":"2014-07"},{"nctId":"NCT01344902","phase":"PHASE1,PHASE2","title":"An Open Dose-finding Study of Oral Applied Hexaminolevulinate (HAL) Imaging in Patients With Suspicion or High Risk of Neoplasia in the Colon","status":"TERMINATED","sponsor":"Photocure","startDate":"2009-02","conditions":["Colon Cancer"],"enrollment":13,"completionDate":""},{"nctId":"NCT00708942","phase":"PHASE2","title":"Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) of Cervical Intraepithelial Neoplasia (CIN) Grade 1","status":"TERMINATED","sponsor":"Photocure","startDate":"2009-01","conditions":["Cervical Intraepithelial Neoplasia"],"enrollment":83,"completionDate":"2012-01"},{"nctId":"NCT00369018","phase":"PHASE1,PHASE2","title":"A Dose-finding Study of MAL and HAL Photodynamic Therapy of Cervical Premalignant Lesions.","status":"COMPLETED","sponsor":"Photocure","startDate":"2006-08","conditions":["Cervical Dysplasia"],"enrollment":96,"completionDate":"2009-07"},{"nctId":"NCT00285701","phase":"PHASE1,PHASE2","title":"Early Detection of Polyps and Colon Cancer by Fluorescence Imaging - a Dose-finding Study","status":"COMPLETED","sponsor":"Photocure","startDate":"2006-07","conditions":["Colorectal Cancer"],"enrollment":38,"completionDate":"2008-03"},{"nctId":"NCT01050309","phase":"PHASE1","title":"An Open-label, Single-dose, Three Period Study to Determine the Pharmacokinetic Parameters of Hexaminolevulinate (HAL) Hydrochloride After Vaginal, Enema and Intravenous Administration of Healthy Female Volunteers","status":"COMPLETED","sponsor":"Photocure","startDate":"2009-11","conditions":["Pharmacokinetics"],"enrollment":8,"completionDate":"2009-12"},{"nctId":"NCT00496171","phase":"","title":"Phase I Study of HAL Formulations Applied to the Cervix in Healthy Volunteers","status":"TERMINATED","sponsor":"Photocure","startDate":"","conditions":["Healthy"],"enrollment":0,"completionDate":""},{"nctId":"NCT00303615","phase":"PHASE2","title":"Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Legacy Health System","startDate":"2005-06","conditions":["Metastatic Breast Cancer"],"enrollment":5,"completionDate":"2007-07"},{"nctId":"NCT00754806","phase":"","title":"Prospective Randomized Comparison of Clinical Results of Hand Assisted Laparoscopic Splenectomies and Open Splenectomies","status":"COMPLETED","sponsor":"Istanbul University","startDate":"2007-02","conditions":["Postoperative Pain"],"enrollment":27,"completionDate":"2008-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET","route":"ORAL","productName":"Androxy"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146093","MMSL":"4747","NDDF":"001250","UNII":"9JU12S4YFY","VUID":"4017725","CHEBI":"CHEBI:5120","VANDF":"4017725","INN_ID":"624","RXNORM":"4494","UMLSCUI":"C0016366","chemblId":"CHEMBL1445","ChEMBL_ID":"CHEMBL1445","KEGG_DRUG":"D00327","DRUGBANK_ID":"DB01185","PUBCHEM_CID":"6446","SNOMEDCT_US":"126125005","IUPHAR_LIGAND_ID":"2861","MESH_DESCRIPTOR_UI":"D005474"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"99%"},"publicationCount":280,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"G03BA01","allCodes":["G03BA01"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturers":3,"_genericFilersChecked":true,"genericManufacturerList":["Upsher Smith Labs","Valeant Pharm Intl","Watson Labs"],"status":"approved","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1956","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1956-10-15T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:14:58.025266+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}